Clinical workflow
California SB 1120: Physician Denial Defense Guide
SB 1120 denial defense: cite HSC §1367.01, demand the reviewing physician's identity, and challenge population-level criteria in grievances.
California SB 1120 Denial Defense: A Physician's Playbook for Medical-Necessity Appeals
Merry AI · Thoughtfully curated clinical briefs.
Clinically reviewed by Dr. Marcus Vance, MD (Medical Informatics Advisor) · Coding review by Kaif R. (Clinical Informatics Specialist) · Sources: CY 2026 CMS PFS, NCCI Policy Manual.
To defend a medical-necessity denial under California SB 1120, require the plan to identify the licensed physician or health care professional who made the decision, show that the denial rested on population-level criteria rather than your patient's documented clinical circumstances, and file a grievance citing Health and Safety Code §1367.01 (or Insurance Code §10123.135 for CDI-regulated insurers). SB 1120, the Physicians Make Decisions Act, took effect January 1, 2025. It allows plans to use algorithms and artificial intelligence in utilization review, but it forbids those tools from replacing individualized clinical judgment, and it reserves every denial, delay, or modification based on medical necessity for a licensed clinician.
This playbook is written for outpatient specialty physicians in cardiology, orthopedics, and other procedure-heavy fields who already have a denial in hand. It covers the statutory text, the elements a compliant denial must contain, a seven-step appeal protocol, documentation benchmarks tied to MDM levels, and the revenue and labor math that make patient-specific documentation sustainable. For the full statewide statutory landscape, see the State AI Scribe Rules & Statutory Compliance Hub.
SB 1120 requires a licensed clinician, not an algorithm, to deny medical necessity
SB 1120 amended two statutes: Health and Safety Code §1367.01, which governs Knox-Keene licensed health care service plans regulated by the Department of Managed Health Care (DMHC), and Insurance Code §10123.135, which governs disability insurers regulated by the California Department of Insurance (CDI). Authored by Senator Josh Becker and signed in September 2024, the law applies to commercial HMOs, most PPO products, and Medi-Cal managed care plans holding Knox-Keene licenses.
The core prohibition is direct: an artificial intelligence, algorithm, or other software tool "shall not deny, delay, or modify health care services based, in whole or in part, on medical necessity." Only a licensed physician, or a licensed health care professional competent to evaluate the specific clinical issues involved, may make that determination. The plan may use software to sort, flag, or approve requests, but an adverse medical-necessity outcome must trace back to a human reviewer with appropriate clinical competence.
The statute also regulates the tools themselves. When a plan uses AI or algorithmic tools for utilization review or utilization management, those tools must base determinations on the enrollee's medical or clinical history, the individual clinical circumstances presented by the requesting provider, and other relevant clinical information in the medical record. They may not rely solely on a group dataset. That single clause is the foundation of every SB 1120 appeal.
Five statutory duties give every outpatient specialist an appeal lever
Each SB 1120 duty maps to a specific argument you can raise in a provider dispute, a peer-to-peer call, or an enrollee grievance. Plans and insurers using AI tools in utilization review must ensure that the tool:
- Uses individual clinical data: the enrollee's history, the provider's presented circumstances, and the medical record, not only aggregate cohort data.
- Does not supplant provider decision-making, meaning the treating physician's documented judgment must be weighed, not overridden by a score.
- Is applied fairly and equitably and does not discriminate, directly or indirectly, against enrollees.
- Remains open to inspection for audit or compliance reviews by DMHC or CDI, with written policies and procedures disclosed as required.
- Is periodically reviewed and revised for accuracy and reliability, and does not use patient data beyond its intended, stated purpose.
Duties one and two carry the most weight in practice. If your note documents a contraindication, a failed therapy, or an objective finding that the denial letter never addresses, you have evidence the determination relied on a group dataset or supplanted your judgment. Duty four matters for escalation: because DMHC and CDI can inspect these tools, a complaint describing a pattern of templated denials gives regulators a concrete reason to audit.
A compliant California denial must name the reviewer and clinical reasons
Health and Safety Code §1367.01(h)(4) already required written denial content before SB 1120, and the new AI rules make those elements far more useful. Every written denial, delay, or modification based on medical necessity must include a clear and concise explanation of the reasons for the decision, a description of the criteria or guidelines used, and the clinical reasons for the medical-necessity determination.
The denial must also list the name and direct telephone number of the health care professional responsible for the decision. A letter signed only by a "Medical Review Department," or one that lists a general call center, is facially incomplete. Under SB 1120, that omission also prevents the plan from showing that a licensed clinician, rather than software, made the call.
Statutory timelines create a second line of defense. Routine prospective decisions are due within five business days of receiving information reasonably necessary to decide, and never later than 14 calendar days. Urgent requests, where the standard timeline could seriously jeopardize life, health, or maximum function, require a decision within 72 hours. The plan must notify the requesting provider within 24 hours of deciding, and must send written notice to the provider and enrollee within two business days.
Callout: A missing reviewer name is a statutory defect, not a formatting issue.
SB 1120 does not reach self-funded ERISA plans or Medicare Advantage
Confirm the plan's regulator first. Self-funded employer plans governed by ERISA are generally exempt from state insurance law, so SB 1120 cannot be cited against them directly. Fee-for-service Medi-Cal is administered by the Department of Health Care Services and follows separate rules. Medicare Advantage is governed by federal law, which preempts most state utilization review standards.
Federal rules offer parallel arguments. Under 42 CFR §422.101(c), Medicare Advantage organizations must base medical-necessity determinations on the individual patient's circumstances, and CMS guidance issued in 2024 states that algorithms predicting length of stay or service need cannot be the sole basis for denial. Under 42 CFR §422.566(d), adverse medical-necessity decisions must be reviewed by a physician or appropriate health care professional with relevant expertise.
The CMS Interoperability and Prior Authorization Final Rule (CMS-0057-F) adds 2026 obligations for Medicare Advantage, Medicaid managed care, CHIP, and federal exchange plans. Beginning January 1, 2026, impacted payers must give a specific reason for prior authorization denials and decide standard requests within seven calendar days and expedited requests within 72 hours. FHIR-based Prior Authorization APIs follow in January 2027, which will make denial reasons machine-readable and easier to contest at scale.
A seven-step protocol turns a denial into a documented statutory violation
Work the steps in order. Each one either resolves the denial or builds the record you will need for a grievance, a DMHC complaint, or an Independent Medical Review (IMR).
Step 1: Identify the regulator and statute
Check the member ID card and plan documents for "DMHC" or "CDI." Cite §1367.01 for DMHC-licensed plans and §10123.135 for CDI-regulated insurers. If the plan is ERISA self-funded or Medicare Advantage, switch to federal arguments.
Step 2: Audit the denial letter for statutory elements
Score the letter against §1367.01(h)(4): explanation of reasons, criteria or guidelines used, clinical reasons, and the reviewer's name and direct telephone number. List every missing element in your appeal.
Step 3: Request the reviewer's identity and specialty
Ask in writing whether the reviewer holds a license in a specialty competent to evaluate the clinical issue. A family physician reviewing a cardiac resynchronization request, or a nurse reviewing a total knee arthroplasty, invites a competency challenge.
Step 4: Request the criteria and the AI disclosure
Request the specific criteria applied (InterQual, MCG, or proprietary guidelines) and ask whether an AI, algorithm, or software tool contributed to the determination. SB 1120 requires plans to maintain written policies on these tools, and the answer shapes your argument.
Step 5: Map your note to the criteria
Build a side-by-side exhibit showing each criterion and the dated chart entry that satisfies it. Highlight any patient-specific factor (contraindication, intolerance, comorbidity, objective finding) the denial did not address. That gap is your evidence of group-dataset reasoning.
Step 6: Use the peer-to-peer strategically
Document the call contemporaneously: date, time, reviewer name, stated specialty, and the specific clinical facts you raised. If the reviewer cannot address an individual circumstance you presented, note it verbatim. That record supports a duty-two (supplanting judgment) argument.
Step 7: Escalate to grievance, complaint, and IMR
Help the patient file a grievance, which the plan must resolve within 30 days (72 hours if urgent). If the plan upholds the denial or misses the deadline, the enrollee may request IMR through DMHC under Health and Safety Code §1374.30. Providers can separately file through the plan's dispute resolution process and submit a provider complaint to DMHC.
Patient-specific documentation is the evidence SB 1120 forces plans to weigh
SB 1120 shifts the burden in a subtle but important way. Because the plan's tool must consider the clinical circumstances you presented, the strength of your appeal depends on how clearly your note presents them. Generic phrases such as "patient failed conservative therapy" give a reviewer nothing to weigh. Dated, quantified, patient-specific facts do.
Cardiology example: chronic systolic heart failure, I50.22
A 64-year-old patient with I50.22 (ICD-10-CM), chronic systolic heart failure, has an LVEF of 30% after 90 days of optimized guideline-directed medical therapy. The cardiologist requests cardiac MRI to distinguish ischemic from nonischemic cardiomyopathy before an ICD decision. The plan denies, citing a transthoracic echo within the past 12 months.
The defense rests on specifics: sacubitril/valsartan, a beta blocker, an MRA, and an SGLT2 inhibitor titrated with dates and doses; LVEF trend from 35% to 30%; NYHA class II to III progression; rising NT-proBNP; and QRS duration documented. The echo cannot characterize myocardial scar, and that clinical reason, absent from the denial, shows a frequency rule replaced individualized review. For cardiology-specific templates, see California SB 1120 Utilization Review Defense.
Orthopedic example: primary osteoarthritis, right knee, M17.11
A 68-year-old patient with M17.11 (ICD-10-CM), unilateral primary osteoarthritis of the right knee, is denied total knee arthroplasty for "insufficient conservative management." The plan's criteria require NSAID trials as part of 12 weeks of conservative care.
The chart documents what matters: 14 weeks of supervised physical therapy, two corticosteroid injections with diminishing relief, Kellgren-Lawrence grade 4 changes on weight-bearing radiographs, a KOOS JR score trending downward, and an NSAID contraindication due to CKD stage 3b (eGFR 38). A uniform NSAID requirement cannot lawfully override a documented contraindication, which is precisely the individual circumstance SB 1120 requires the plan to weigh.
Clinical indicators, MDM thresholds, and audit defenses by scenario
Use this table as a pre-submission checklist. The MDM column reflects 2021 AMA E/M guidelines as adopted by CMS, and the audit defense column states the SB 1120 argument each documentation element supports.
| Clinical scenario | Patient-specific indicators to document | MDM threshold | SB 1120 audit defense |
|---|---|---|---|
| I50.22 chronic systolic HF, advanced imaging or device request | LVEF trend with dates, NYHA class, GDMT agents and doses, NT-proBNP, QRS duration | Moderate (99214): chronic illness with progression plus prescription drug management. High (99215): severe exacerbation. | Denial must show a competent reviewer weighed GDMT history, not only imaging frequency rules. |
| M17.11 right knee OA, arthroplasty request | KL grade, weeks of PT, injection dates and response, NSAID contraindication, functional score | High (99215): decision regarding elective major surgery with identified patient risk factors. | Uniform conservative-care rules cannot override a documented contraindication. |
| Repeat advanced imaging within frequency limits | New or changed symptoms, interval exam change, prior study limitations | Moderate: undiagnosed new problem with uncertain prognosis, or illness with progression. | Frequency caps are group-dataset rules; interval change is an individual circumstance. |
| Specialty drug or step-therapy override | Prior agents, dates, adverse reactions, lab contraindications | Moderate: prescription drug management. High: drug therapy requiring intensive toxicity monitoring. | Documented intolerance must appear in the denial's clinical reasons. |
| G2211 longitudinal specialty care | Ongoing relationship, specialist as continuing focal point for a serious or complex condition | Not MDM-based; add-on to office E/M codes 99202 through 99215. | Continuity documentation proves the treating physician's sustained individual judgment. |
G2211 complexity capture recovers $15,600+ per year from the same documentation
The same longitudinal documentation that defends a denial also supports HCPCS G2211, the office and outpatient E/M visit complexity add-on. CMS pays G2211 when the practitioner serves as the continuing focal point for all needed services or provides ongoing care for a single serious or complex condition. Managing chronic heart failure across GDMT titration, or guiding a patient through progressive osteoarthritis toward a surgical decision, fits that definition when the note says so.
The revenue math is straightforward. At a CY 2026 national payment of roughly $16 per claim, a specialist who captures G2211 on about 20 eligible established-patient visits per week across 48 working weeks recovers more than $15,600 per year. Many specialty practices leave this revenue uncollected because notes describe the visit but not the longitudinal relationship.
Know the NCCI and CMS boundaries. G2211 is not payable when the base E/M is reported with modifier 25, except when the E/M is billed with modifier 25 on the same day as an annual wellness visit, vaccine administration, or a Medicare Part B preventive service. A visit whose primary purpose is a minor procedure with a separately reported E/M will usually not qualify.
Callout: Longitudinal notes defend denials and capture G2211 in a single workflow.
Documentation labor costs $48,000 per MA; Merry AI Pro costs 1.3%
Patient-specific documentation takes time, and most specialty practices absorb that time through medical assistant hours spent on chart prep, prior authorization packets, and appeal exhibits. A fully loaded medical assistant (wages, payroll taxes, and benefits) costs a California practice approximately $48,000 per year, and much of that time goes to reconstructing clinical facts that were spoken aloud in the exam room but never captured in the note.
Merry AI Pro costs $54 per month on an annual plan, or $648 per year. That equals about 1.3% of a single fully loaded MA. The ambient scribe captures dated medication trials, contraindications, objective findings, and longitudinal reasoning during the encounter, and the physician reviews and signs every note. The result is a record that already contains the individual clinical circumstances an SB 1120 appeal requires.
The economic case compounds. One overturned arthroplasty denial or one approved cardiac MRI often exceeds the annual subscription many times over, before counting G2211 capture or MA hours redirected to patient care.
AI in your own workflow triggers California AB 3030 disclosure duties
SB 1120 regulates payers, while a companion law regulates providers. AB 3030, effective January 1, 2025, requires health facilities, clinics, and physician offices that use generative AI to create patient communications containing clinical information to include a disclaimer stating the message was AI-generated and instructions for reaching a human health care provider.
The disclosure requirement does not apply when a licensed or certified provider reads and reviews the AI-generated communication before it is sent. Physician-reviewed visit notes and appeal letters therefore sit in a different category than unreviewed patient portal replies. For the full framework, see California AB 3030 Generative AI Disclosure Requirements.
Consistency strengthens your position. A practice that insists payers keep a licensed human in every denial should model the same standard internally: AI drafts, the physician decides, and the signed record shows it.
SB 1120 appeal letters should cite statute, record, and missing elements
Adapt the following excerpt to your case. Keep it factual, cite the statute once, and let the dated chart entries carry the argument.
This appeal concerns the denial dated March 4, 2026, of cardiac MRI for a patient with chronic systolic heart failure (I50.22). Under Health and Safety Code §1367.01, as amended by SB 1120, a medical-necessity denial must be made by a licensed health care professional competent to evaluate the specific clinical issues and must rest on the enrollee's individual clinical circumstances, not solely on a group dataset.
The denial letter omits the reviewer's name and direct telephone number and does not state clinical reasons addressing the enclosed GDMT titration record, LVEF decline from 35% to 30%, or progression to NYHA class III. Please identify the reviewer and specialty, disclose whether an algorithmic tool contributed, and reconsider in light of the attached exhibit.
Attach the criteria-to-chart exhibit from Step 5, the peer-to-peer log from Step 6, and the relevant signed notes. Send by a trackable method and calendar the statutory response deadlines.
Frequently asked questions about California SB 1120 denial defense
Does SB 1120 apply to Medi-Cal managed care plans?
Yes, for Medi-Cal managed care plans licensed under the Knox-Keene Act, because SB 1120 amends Health and Safety Code §1367.01. Fee-for-service Medi-Cal, self-funded ERISA plans, and Medicare Advantage fall outside its direct reach, so confirm the plan's licensure before citing the statute in an appeal.
Can a health plan still use AI in utilization review?
Yes. SB 1120 permits algorithms and AI tools, but they must rely on the enrollee's individual clinical history and circumstances, cannot supplant provider decision-making, and must remain open to regulator inspection. Only a licensed physician or competent licensed health care professional may deny, delay, or modify care for medical necessity.
What must a written medical-necessity denial include in California?
Under §1367.01(h)(4), the written denial must give a clear and concise explanation of the reasons, describe the criteria or guidelines used, state the clinical reasons for the medical-necessity decision, and list the name and direct telephone number of the responsible health care professional. Missing elements support a grievance.
How fast must a California plan decide a prior authorization request?
Routine prospective decisions are due within five business days of receiving reasonably necessary information, capped at 14 calendar days. Urgent requests, where delay threatens life, health, or function, require a decision within 72 hours. The plan must notify the requesting provider within 24 hours of deciding.
How does an ambient AI scribe help defend an SB 1120 denial?
An ambient scribe like Merry AI captures the patient-specific history, failed therapies, and objective findings that SB 1120 requires plans to weigh. The physician reviews and signs every note, so the record reflects licensed clinical judgment and gives appeals concrete evidence against population-level algorithmic denials.